Injectable tumor necrosis factor α inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager database
- PMID: 23754789
- DOI: 10.1002/acr.22053
Injectable tumor necrosis factor α inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager database
Abstract
Objective: To estimate the incidence and rate of outpatient antibiotic and antiviral medication use among children receiving methotrexate and/or an injectable tumor necrosis factor α (iTNFα) inhibitor (etanercept and/or adalimumab)and to compare these rates with those of a control population.
Methods: Data were obtained from a pharmacy benefit manager (PBM) database. Children were included if they had >1 prescription claim for an iTNFα inhibitor or methotrexate prescribed by a pediatric or adult rheumatologist between 2008 and 2010 and if they were age <18 years at the time of the claim. A control cohort of randomly selected children was generated from the PBM database. Poisson regression was used to compare antimicrobial rate ratios (RRs). Incidence rates and RRs were adjusted for age, sex, and prednisone exposure.
Results: In total, 4,312 children were included. The adjusted RRs for antibiotic prescriptions among children receiving methotrexate monotherapy or iTNFα inhibitor and methotrexate combination therapy compared with the control cohort were 2.18 (95% confidence interval [95% CI] 1.92–2.47) and 2.12 (95% CI 1.79–2.50), respectively. The adjusted RRs for antiviral prescriptions among children receiving methotrexate monotherapy or iTNFα inhibitor and methotrexate combination therapy compared with the control cohort were 3.67 (95% CI 1.98–6.78) and 4.34 (95% CI 1.86–10.14), respectively. The RRs for the iTNFα inhibitor group were similar in magnitude. There was no significant difference in RRs between the medication exposure categories for either antibiotic or antiviral prescriptions.
Conclusion: Children receiving methotrexate and/or an iTNFα inhibitor had higher rates of antibiotic and antiviral use compared with the control cohort. Data sets with additional patient-level and disease-specific data are required to assess this association in more detail.
Similar articles
-
Methotrexate and injectable tumor necrosis factor-α inhibitor adherence and persistence in children with rheumatic diseases.J Rheumatol. 2013 Jan;40(1):80-6. doi: 10.3899/jrheum.120753. Epub 2012 Nov 1. J Rheumatol. 2013. PMID: 23118115
-
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8. J Med Econ. 2012. PMID: 22115327
-
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002. Clin Ther. 2009. PMID: 19446156
-
The epidemiology of prescriptions abandoned at the pharmacy.Ann Intern Med. 2010 Nov 16;153(10):633-40. doi: 10.7326/0003-4819-153-10-201011160-00005. Ann Intern Med. 2010. PMID: 21079218
-
Pediatric rheumatology for the adult rheumatologist I: therapy and dosing for pediatric rheumatic disorders.J Clin Rheumatol. 2005 Feb;11(1):21-33. doi: 10.1097/01.rhu.0000152151.12999.76. J Clin Rheumatol. 2005. PMID: 16357693 Review.
Cited by
-
Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.Clin Rheumatol. 2020 Mar;39(3):853-860. doi: 10.1007/s10067-019-04804-x. Epub 2019 Nov 16. Clin Rheumatol. 2020. PMID: 31732822
-
[Immunization in children and adolescents with rheumatic and musculoskeletal diseases].Z Rheumatol. 2014 Dec;73(10):878-89. doi: 10.1007/s00393-014-1396-x. Z Rheumatol. 2014. PMID: 25479932 German.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
